Corporate Information
CEO Message
Mission
Corporate Information
Corporate Governance
Business
Stemrim History
About “Regeneration-Inducing Medicine
™
”
What is “Regeneration-Inducing Medicine
™
”?
Issues of Conventional Cell Therapy
The Superiority of “Regeneration-Inducing Medicine
™
”
Business
Areas of Disease and Pipeline
“Regeneration-Inducing Medicine
™
”
Autologous cell sampling devices for medical treatment
Stem cells gene therapy
Research Paper
Investor Relations
COO Message
Investor News
ESG
Financial Data
Investor Library
Investor Calendar
Analyst Coverage
Stock Prices
Investor Relations
Timely Disclosure Information
March 13, 2024
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
February 29, 2024
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators
February 15, 2024
StemRIM Announces Patent Registration (Japan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, and Disseverance Osteochondritis
February 14, 2024
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators
January 31, 2024
StemRIM Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, Disseverance Osteochondritis, etc.)
Click here for past list
StemRIM
>
Investor Relations
>
Investor Library
>
Timely Disclosure Information
